Gain Therapeutics, Inc.

Stage 4 · Declining · week 5

As of Oct 22, 2026, Gain Therapeutics is in Stage 4, the downtrend phase, now in week 5 (since Sep 21, 2026). It closed at $1.29, 69.1% below its 52-week high and below its 200-day average, which is falling.

$1.29

+7.50% today

$56.3M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is GANX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 20w

S4 18w

S4 13w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S3 1w → S4 20w → S1 6w → S2 7w → S3 4w → S4 18w → S1 13w → S4 5w → S3 1w → S2 8w → S3 8w → S4 18w → S1 6w → S2 11w → S3 7w → S4 4w → S1 3w → S4 13w → S1 5w → S4 5w current

Total tracked: 165 weeks across 20 stage runs.

GANX among Biotechnology312th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…312	GANXGain Therapeutics, Inc.	Stage 4 · wk 5	29	−29.9%

vs 52W High

-69.1%

$1.19 lo$4.18 hi

69.1% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 5

1w13w26w

Week 5, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-31.9%

200 DMA: $1.89 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

5.98x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-29.9%

-26.3%

-31.7%

YTD

-59.4%

-38.6%

Scan Membership

Breakout Watch

Latest: 2025-02-05

3 appearances in last 60 days. First seen: 2023-02-08.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 5 · Vol 5.98x

2026-10-21S4

Wk 5 · Vol 1.25x

2026-10-20S4

Wk 5 · Vol 1.07x

2026-10-19S4

Wk 5 · Vol 1.13x

2026-10-16S4

Wk 4 · Vol 0.99x

2026-10-15S4

Wk 4 · Vol 1.07x

2026-10-14S4

Wk 4 · Vol 1.87x

2026-10-13S4

Wk 4 · Vol 1.77x

2026-10-12S4

Wk 4 · Vol 0.72x

2026-10-09S4

Wk 3 · Vol 0.73x

2026-10-08S4

Wk 3 · Vol 0.79x

2026-10-07S4

Wk 3 · Vol 0.82x

Moving averages & range

50 DMA

$1.73

200 DMA

$1.89

52W High

$4.18

52W Low

$1.19

5D Low

$1.19

Resistance levels (recent highs)

20d High

$1.78

60d High

$2.17

120d High

$2.17

250d High

$4.18

Next resistance

+38.0%

to 20d High

ROE

-268.3%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 4.9

Gain Therapeutics: quick answers

What stage is Gain Therapeutics in?

As of Oct 22, 2026, Gain Therapeutics (GANX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 21, 2026 and is in week 5. What the four stages mean

Is Gain Therapeutics in an uptrend?

No. Gain Therapeutics is in a Stage 4 downtrend. It trades 31.9% below its 200-day average, which is falling.

How far is Gain Therapeutics from its 52-week high?

Gain Therapeutics closed at $1.29 on Oct 22, 2026, 69.1% below its 52-week high of $4.18. Its 52-week low is $1.19.

How has Gain Therapeutics performed over the past year?

As of Oct 22, 2026, Gain Therapeutics is down 38.6% over the past year and down 59.4% so far in 2026.

Which sector and industry is Gain Therapeutics in?

Gain Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.